Advertisement
UK markets close in 5 hours 4 minutes

  • FTSE 100

    8,091.57
    +51.19 (+0.64%)
     

  • FTSE 250

    19,724.30
    +4.93 (+0.03%)
     

  • AIM

    755.42
    +0.73 (+0.10%)
     

  • GBP/EUR

    1.1669
    +0.0024 (+0.21%)
     

  • GBP/USD

    1.2520
    +0.0058 (+0.46%)
     

  • Bitcoin GBP

    50,691.21
    -2,329.49 (-4.39%)
     

  • CMC Crypto 200

    1,357.27
    -25.31 (-1.83%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.84
    +0.03 (+0.04%)
     

  • GOLD FUTURES

    2,338.00
    -0.40 (-0.02%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,982.47
    -106.23 (-0.59%)
     

  • CAC 40

    8,040.58
    -51.28 (-0.63%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

AstraZeneca R&D executive Morrison to lead cancer firm Syndax

Reuters - UK Focus

LONDON, June 15 (Reuters) - AstraZeneca (NYSE: AZN - news) 's outgoing chief medical officer and head of global late-stage drug development Briggs Morrison, whose departure from the British drugmaker was announced last week, is to head U.S. cancer firm Syndax Pharmaceuticals.

Syndax said on Monday that as its chief executive he would help take the privately owned company to the next level as it develops a drug called entinostat that modulates the immune system in the fight against tumours.

The U.S. company is already collaborating with Merck (Swiss: MER.SW - news) to evaluate entinostat in combination with Keytruda to treat lung cancer and melanoma.

Morrison's exit leaves a gap at the top of AstraZeneca's research operations. (Reporting by Ben Hirschler, editing by Louise Heavens)